The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Blood mRNA signature to predict survival in patients with metastatic melanoma treated with tremelimumab.
Yvonne M. Saenger
No relevant relationships to disclose
Jay Magidson
Employment or Leadership Position - Statistical Innovations
Stock Ownership - Statistical Innovations
Bobby Chi-Hung Liaw
No relevant relationships to disclose
Karl Wassmann
Research Funding - Pfizer
William Barker
Employment or Leadership Position - Statistical Innovations
Sara Harcharik
No relevant relationships to disclose
David Fisher
No relevant relationships to disclose
William K. Oh
No relevant relationships to disclose
Philip Friedlander
No relevant relationships to disclose